Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2010. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of August 31, 2010:
- Total issued Ordinary shares: 5,666,995,568 (25p each).
- Treasury shares held: 474,194,158.
- Total voting rights: 5,192,801,410.
No material changes in financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,192,801,410) for compliance with Financial Services Authority Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (474,194,158) as of August 31, 2010.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.